The narrative about pancreatitis and Ozempic/ GLP-1's gets obliterated by new study
Hey Peptide Insiders,
It’s your trusted source, Sean Davis, bringing you the freshest scoop from the world of peptides. Grab your coffee, sit back, and get ready to marvel at how GLP-1 receptor agonists are shaking things up!
OOPS!
The narrative being pushed was to be scared of Ozempic because it causes pancreatitis?
New "tiny" study of 638k people says it reduces chance of pancreatitis!
Oh wait, what? the media is wrong???
Don't trust the narrative. GLP-1's have the power to change our obese culture and wipe out the need for 100's of drugs and put big food out of business.
They be scared of the big bad GLP-1 gorilla.
read for yourself holmes...
A Revolutionary Breakthrough at ENDO 2024
So, you’ve probably seen the cautious glances and heard the hushed whispers around GLP-1 medications. Who could blame folks? The fear of pancreatitis recurrence had everyone on edge. But, hold onto your hats because this boat just got rocked at ENDO 2024.
Dr. Mahmoud Nassar and his team unraveled some juicy secrets from the TriNetX database. Picture a gigantic treasure chest packed with data from 127 million patients across 15 countries—primarily from the good ol’ U.S. of A. The team zeroed in on 638,501 people who've tangoed with acute pancreatitis. Their goal? To decipher how different diabetes and obesity meds are playing with the risk of another pancreatic punch.
The Data Symphony: GLP-1 vs. the Rest
Simply put, GLP-1 receptor agonists are the superheroes we need. When compared to the other heavy-hitters, it’s like seeing Captain America outdo Iron Man. Patients on GLP-1 meds had a noticeably lower chance of getting smacked down by pancreatitis again. Check these out:
- GLP-1 users vs. SGLT2 inhibitors: 15.2% recurrence with GLP-1 vs. 24% with SGLT2i.
- GLP-1 users vs. DPP4 inhibitors: 14.4% recurrence with GLP-1 vs. 23.3% with DPP4i.
- And the mic-drop moment, GLP-1 users vs. no specific meds: 14.5% recurrence with GLP-1 vs. a whopping 51.6% in the “hope is not a strategy” group.
It’s safe to say GLP-1 receptor agonists are making their mark, and their entrance is louder than a rock concert.
Read the study for yourself here: https://medicalxpress.com/news/2024-05-glp-medications-diabetes-obesity-acute.html
A Future Painted with Hope
Nassar spells out loud and clear: This isn’t just a finding—it’s an epiphany. It questions the old-school panic about pancreatitis and propels us towards a future where GLP-1 receptor agonists are front and center in managing diabetes and obesity. The real kicker? This could mean a huge leap in the quality of life for countless individuals. Personalized medicine is no longer just a buzzword—it’s here to stay, and GLP-1 is its poster child.
Wrapping Up
There you have it, folks. GLP-1 receptor agonists are rewriting the treatment chapters for type 2 diabetes and obesity. The days of treating these conditions with crossed fingers are over. We’re stepping into an era where confidence in GLP-1 is as solid as a rock.
Stay tuned, Peptide Insiders, because this is just the beginning. GLP-1’s are here to stay, and they’re changing lives in a big, wonderful way.
Until next time, stay strong and peptide on!
Yours in health, Sean Davis